State Street Corp Kaleido Biosciences, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.05 - $1.7 $21,751 - $739,540	-435,024 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.3 - $2.7 $6,548 - $13,599	5,037 Added 1.17%	435,024 $718,000
Q4 2021 Feb 14, 2022	SELL	$2.39 - $6.02 $33,022 - $83,178	-13,817 Reduced 3.11%	429,987 $1.03 Million
Q3 2021 Nov 15, 2021	BUY	$5.36 - $7.99 $363,927 - $542,497	67,897 Added 18.06%	443,804 $2.42 Million
Q2 2021 Aug 16, 2021	BUY	$5.82 - $8.72 $1.02 Million - $1.53 Million	175,243 Added 87.33%	375,907 $2.8 Million
Q1 2021 May 17, 2021	BUY	$7.2 - $16.82 $84,391 - $197,147	11,721 Added 6.2%	200,664 $1.63 Million
Q4 2020 Feb 16, 2021	BUY	$5.77 - $11.33 $124,054 - $243,595	21,500 Added 12.84%	188,943 $1.72 Million
Q3 2020 Nov 10, 2020	SELL	$5.09 - $11.07 $30,550 - $66,442	-6,002 Reduced 3.46%	167,443 $1.85 Million
Q2 2020 Aug 14, 2020	BUY	$4.62 - $8.01 $120,854 - $209,533	26,159 Added 17.76%	173,445 $1.29 Million
Q1 2020 May 11, 2020	BUY	$3.62 - $9.49 $533,175 - $1.4 Million	147,286 New	147,286 $906,000

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.